FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2057685090> ?p ?o ?g. }

• W2057685090 endingPage "684" @default.
• W2057685090 startingPage "675" @default.
• W2057685090 abstract "Background The potential for cyclo-oxygenase 2 (COX2)-selective inhibitors to increase the risk for myocardial infarction is controversial. The Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET) aimed to assess gastrointestinal and cardiovascular safety of the COX2 inhibitor lumiracoxib compared with two non-steroidal anti-inflammatory drugs, naproxen and ibuprofen. Methods 18 325 patients age 50 years or older with osteoarthritis were randomised to lumiracoxib 400 mg once daily (n=9156), naproxen 500 mg twice daily (4754), or ibuprofen 800 mg three times daily (4415) in two substudies of identical design. Randomisation was stratified for low-dose aspirin use and age. The primary cardiovascular endpoint was the Antiplatelet Trialists' Collaboration endpoint of non-fatal and silent myocardial infarction, stroke, or cardiovascular death. Analysis was by intention to treat. Findings 81 (0·44%) patients did not start treatment and 7120 (39%) did not complete the study. At 1-year follow-up, incidence of the primary endpoint was low, both with lumiracoxib (59 events [0·65%]) and the non-steroidal anti-inflammatory drugs (50 events [0·55%]; hazard ratio 1·14 [95% CI 0·78–1·66], p=0·5074). Incidence of myocardial infarction (clinical and silent) in the overall population in the individual substudies was 0·38% with lumiracoxib (18 events) versus 0·21% with naproxen (ten) and 0·11% with lumiracoxib (five) versus 0·16% with ibuprofen (seven). In the naproxen substudy, rates of myocardial infarction (clinical and silent) did not differ significantly compared with lumiracoxib in the population not taking low-dose aspirin (hazard ratio 2·37 [95% CI 0·74–7·55], p=0·1454), overall (1·77 [0·82–3·84], p=0·1471), and in patients taking aspirin (1·36 [0·47–3·93], p=0·5658). In the ibuprofen substudy, these rates did not differ between lumiracoxib and ibuprofen in the population not taking low-dose aspirin (0·75 [0·20–2·79], p=0·6669), overall (0·66 [0·21–2·09], p=0·4833), and in patients taking aspirin (0·47 [0·04–5·14], p=0·5328). Interpretation The primary endpoint, including incidence of myocardial infarction, did not differ between lumiracoxib and either ibuprofen or naproxen, irrespective of aspirin use. This finding suggests that lumiracoxib is an appropriate treatment for patients with osteoarthritis, who are often at high cardiovascular risk and taking low-dose aspirin." @default.
• W2057685090 created "2016-06-24" @default.
• W2057685090 creator A5000779664 @default.
• W2057685090 creator A5012985677 @default.
• W2057685090 creator A5015121992 @default.
• W2057685090 creator A5018277744 @default.
• W2057685090 creator A5018338106 @default.
• W2057685090 creator A5018445266 @default.
• W2057685090 creator A5021983006 @default.
• W2057685090 creator A5026165132 @default.
• W2057685090 creator A5028822431 @default.
• W2057685090 creator A5043621364 @default.
• W2057685090 creator A5060370891 @default.
• W2057685090 creator A5061928513 @default.
• W2057685090 creator A5064599465 @default.
• W2057685090 creator A5065978967 @default.
• W2057685090 creator A5071249249 @default.
• W2057685090 creator A5073833664 @default.
• W2057685090 creator A5086691347 @default.
• W2057685090 creator A5089513520 @default.
• W2057685090 date "2004-08-01" @default.
• W2057685090 modified "2023-10-17" @default.
• W2057685090 title "Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial" @default.
• W2057685090 cites W1565253767 @default.
• W2057685090 cites W1995355693 @default.
• W2057685090 cites W1995528018 @default.
• W2057685090 cites W2002178040 @default.
• W2057685090 cites W2011327495 @default.
• W2057685090 cites W2013166307 @default.
• W2057685090 cites W2018035901 @default.
• W2057685090 cites W2020563114 @default.
• W2057685090 cites W2024233889 @default.
• W2057685090 cites W2027451784 @default.
• W2057685090 cites W2031340028 @default.
• W2057685090 cites W2063252400 @default.
• W2057685090 cites W2065689558 @default.
• W2057685090 cites W2099647468 @default.
• W2057685090 cites W2104379105 @default.
• W2057685090 cites W2106346422 @default.
• W2057685090 cites W2114949308 @default.
• W2057685090 cites W2118794261 @default.
• W2057685090 cites W2134913491 @default.
• W2057685090 cites W2137408480 @default.
• W2057685090 cites W2138224872 @default.
• W2057685090 cites W2141659719 @default.
• W2057685090 cites W2143995569 @default.
• W2057685090 cites W2163756514 @default.
• W2057685090 cites W2172253009 @default.
• W2057685090 cites W2330496155 @default.
• W2057685090 cites W3139427245 @default.
• W2057685090 cites W4239471829 @default.
• W2057685090 doi "https://doi.org/10.1016/s0140-6736(04)16894-3" @default.
• W2057685090 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15325832" @default.
• W2057685090 hasPublicationYear "2004" @default.
• W2057685090 type Work @default.
• W2057685090 sameAs 2057685090 @default.
• W2057685090 citedByCount "458" @default.
• W2057685090 countsByYear W20576850902012 @default.
• W2057685090 countsByYear W20576850902013 @default.
• W2057685090 countsByYear W20576850902014 @default.
• W2057685090 countsByYear W20576850902015 @default.
• W2057685090 countsByYear W20576850902016 @default.
• W2057685090 countsByYear W20576850902017 @default.
• W2057685090 countsByYear W20576850902018 @default.
• W2057685090 countsByYear W20576850902019 @default.
• W2057685090 countsByYear W20576850902020 @default.
• W2057685090 countsByYear W20576850902022 @default.
• W2057685090 countsByYear W20576850902023 @default.
• W2057685090 crossrefType "journal-article" @default.
• W2057685090 hasAuthorship W2057685090A5000779664 @default.
• W2057685090 hasAuthorship W2057685090A5012985677 @default.
• W2057685090 hasAuthorship W2057685090A5015121992 @default.
• W2057685090 hasAuthorship W2057685090A5018277744 @default.
• W2057685090 hasAuthorship W2057685090A5018338106 @default.
• W2057685090 hasAuthorship W2057685090A5018445266 @default.
• W2057685090 hasAuthorship W2057685090A5021983006 @default.
• W2057685090 hasAuthorship W2057685090A5026165132 @default.
• W2057685090 hasAuthorship W2057685090A5028822431 @default.
• W2057685090 hasAuthorship W2057685090A5043621364 @default.
• W2057685090 hasAuthorship W2057685090A5060370891 @default.
• W2057685090 hasAuthorship W2057685090A5061928513 @default.
• W2057685090 hasAuthorship W2057685090A5064599465 @default.
• W2057685090 hasAuthorship W2057685090A5065978967 @default.
• W2057685090 hasAuthorship W2057685090A5071249249 @default.
• W2057685090 hasAuthorship W2057685090A5073833664 @default.
• W2057685090 hasAuthorship W2057685090A5086691347 @default.
• W2057685090 hasAuthorship W2057685090A5089513520 @default.
• W2057685090 hasConcept C126322002 @default.
• W2057685090 hasConcept C142724271 @default.
• W2057685090 hasConcept C168563851 @default.
• W2057685090 hasConcept C203092338 @default.
• W2057685090 hasConcept C204787440 @default.
• W2057685090 hasConcept C207103383 @default.
• W2057685090 hasConcept C2777077863 @default.
• W2057685090 hasConcept C2777628954 @default.
• W2057685090 hasConcept C2778115740 @default.
• W2057685090 hasConcept C2779944601 @default.
• W2057685090 hasConcept C2908647359 @default.

• next